Drug delivery strategy utilizing conjugation via reversible disulfide linkages: Role and site of cellular reducing activities

Advanced Drug Delivery Reviews

Volumn 55, Issue 2, 2003, Pages 199-215

  Saito, Go ^a,c   Swanson, Joel A ^b   Lee, Kyung Dall ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c DAIICHI SANKYO CO   (Japan)

Author keywords

Bioconjugate; Disulfide bond; Glutathione (GSH); Macromolecular delivery; Protein disulfide isomerase (PDI); Reduction; Interferon inducible lysosomal thiol reductase (GILT)

Indexed keywords

CHEMICAL BONDS; ENZYMES; SULFUR;

DRUG CONJUGATES;

DRUG PRODUCTS;

CELL ENZYME; CYSTEINE; DISULFIDE; OXIDOREDUCTASE; THIOL DERIVATIVE;

CELL SURFACE; CONJUGATION; COVALENT BOND; CYTOSOL; DISULFIDE BOND; DRUG DELIVERY SYSTEM; DRUG FORMULATION; ENDOSOME; HUMAN; LYSOSOME; MACROMOLECULE; NONHUMAN; OXIDATION; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; REVIEW;

EID: 0347926091     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(02)00179-5     Document Type: Article

References (134)

1. Dubowchik G.M., Walker M.A. Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs. Pharmacol. Ther. 83:1999;67-123.
2. Garnett M.C. Targeted drug conjugates: principles and progress. Adv. Drug Deliv. Rev. 53:2001;171-216.
3. Falnes P.O., Sandvig K. Penetration of protein toxins into cells. Curr. Opin. Cell Biol. 12:2000;407-413.
4. Chang T.M., Neville D.M. Jr. Artificial hybrid protein containing a toxic protein fragment and a cell membrane receptor-binding moiety in a disulfide conjugate. I. Synthesis of diphtheria toxin fragment A-S-S-human placental lactogen with methyl-5-bromovalerimidate. J. Biol. Chem. 252:1977;1505-1514.
5. King T.P., Li Y., Kochoumian L. Preparation of protein conjugates via intermolecular disulfide bond formation. Biochemistry (Moscow). 17:1978;1499-1506.
6. Gilliland D.G., Collier R.J., Moehring J.M., Moehring T.J. Chimeric toxins: toxic, disulfide-linked conjugate of concanavalin A with fragment A from diphtheria toxin. Proc. Natl. Acad. Sci. USA. 75:1978;5319-5323.
7. Feener E.P., Shen W.C., Ryser H.J. Cleavage of disulfide bonds in endocytosed macromolecules. A processing not associated with lysosomes or endosomes. J. Biol. Chem. 265:1990;18780-18785.
8. Hwang C., Sinskey A.J., Lodish H.F. Oxidized redox state of glutathione in the endoplasmic reticulum. Science. 257:1992;1496-1502.
9. Martensson J., Lai J.C., Meister A. High-affinity transport of glutathione is part of a multicomponent system essential for mitochondrial function. Proc. Natl. Acad. Sci. USA. 87:1990;7185-7189.
10. Lash L.H., Qian W., Putt D.A., Hueni S.E., Elfarra A.A., Krause R.J., Parker J.C. Renal and hepatic toxicity of trichloroethylene and its glutathione-derived metabolites in rats and mice: sex-, species-, and tissue-dependent differences. J. Pharmacol. Exp. Ther. 297:2001;155-164.
11. Arner E.S., Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur. J. Biochem. 267:2000;6102-6109.
12. Holmgren A., Bjornstedt M. Thioredoxin and thioredoxin reductase. Methods Enzymol. 252:1995;199-208.
13. Holmgren A. Thioredoxin and glutaredoxin systems. J. Biol. Chem. 264:1989;13963-13966.
14. Darby N.J., Freedman R.B., Creighton T.E. Dissecting the mechanism of protein disulfide isomerase: catalysis of disulfide bond formation in a model peptide. Biochemistry (Moscow). 33:1994;7937-7947.
15. Meister A. Glutathione. Annu. Rev. Biochem. 52:1983;711-760.
16. Gilbert H.F. Thiol/disulfide exchange equilibria and disulfide bond stability. Exp. Neurol. 132:1995;54-61.
17. Meister A. Glutathione deficiency produced by inhibition of its synthesis, and its reversal: applications in research and therapy. Pharmacol. Ther. 51:1991;155-194.
18. Donoghue N., Yam P.T., Jiang X.M., Hogg P.J. Presence of closely spaced protein thiols on the surface of mammalian cells. Protein Sci. 9:2000;2436-2445.
19. Noiva R. Protein disulfide isomerase: the multifunctional redox chaperone of the endoplasmic reticulum. Semin. Cell Dev. Biol. 10:1999;481-493.
20. Griffiths G. Localization of the Lys, Asp, Glu, Leu tetrapeptide receptor to the Golgi complex and the intermediate compartment in mammalian cells. J. Cell Biol. 127:1994;1557-1574.
21. Yoshimori T., Semba T., Takemoto H., Akagi S., Yamamoto A., Tashiro Y. Protein disulfide-isomerase in rat exocrine pancreatic cells is exported from the endoplasmic reticulum despite possessing the retention signal. J. Biol. Chem. 265:1990;15984-15990.
22. Jiang X.M., Fitzgerald M., Grant C.M., Hogg P.J. Redox control of exofacial protein thiols/disulfides by protein disulfide isomerase. J. Biol. Chem. 274:1999;2416-2423.
23. Couet J. Cell surface protein disulfide-isomerase is involved in the shedding of human thyrotropin receptor ectodomain. Biochemistry (Moscow). 35:1996;14800-14805.
24. Tager M. Membrane-bound protein disulfide isomerase (PDI) is involved in regulation of surface expression of thiols and drug sensitivity of B-CLL cells. Exp. Hematol. 25:1997;601-607.
25. Lahav J., Gofer-Dadosh N., Luboshitz J., Hess O., Shaklai M. Protein disulfide isomerase mediates integrin-dependent adhesion. FEBS Lett. 475:2000;89-92.
26. Terada K. Secretion, surface localization, turnover, and steady state expression of protein disulfide isomerase in rat hepatocytes. J. Biol. Chem. 270:1995;20410-20416.
27. Akagi S. Localization of protein disulfide isomerase on plasma membranes of rat exocrine pancreatic cells. J. Histochem. Cytochem. 36:1988;1069-1074.
28. Mandel R., Ryser H.J., Ghani F., Wu M., Peak D. Inhibition of a reductive function of the plasma membrane by bacitracin and antibodies against protein disulfide-isomerase. Proc. Natl. Acad. Sci. USA. 90:1993;4112-4116.
29. Yamaizumi M., Mekada E., Uchida T., Okada Y. One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell. 15:1978;245-250.
30. Falnes P.O., Olsnes S. Cell-mediated reduction and incomplete membrane translocation of diphtheria toxin mutants with internal disulfides in the A fragment. J. Biol. Chem. 270:1995;20787-20793.
31. Papini E., Rappuoli R., Murgia M., Montecucco C. Cell penetration of diphtheria toxin. Reduction of the interchain disulfide bridge is the rate-limiting step of translocation in the cytosol. J. Biol. Chem. 268:1993;1567-1574.
32. Ryser H.J., Mandel R., Ghani F. Cell surface sulfhydryls are required for the cytotoxicity of diphtheria toxin but not of ricin in Chinese hamster ovary cells. J. Biol. Chem. 266:1991;18439-18442.
33. Chueh P.J., Morre D.M., Morre D.J. A site-directed mutagenesis analysis of tNOX functional domains. Biochim. Biophys. Acta. 1594:2002;74-83.
34. Morre D.J., Chueh P.J., Lawler J., Morre D.M. The sulfonylurea-inhibited NADH oxidase activity of HeLa cell plasma membranes has properties of a protein disulfide-thiol oxidoreductase with protein disulfide-thiol interchange activity. J. Bioenerg. Biomembr. 30:1998;477-487.
35. Morre D.J., Morre D.M. Differential response of the NADH oxidase of plasma membranes of rat liver and hepatoma and HeLa cells to thiol reagents. J. Bioenerg. Biomembr. 27:1995;137-144.
36. Sahaf B., Soderberg A., Spyrou G., Barral A.M., Pekkari K., Holmgren A., Rosen A. Thioredoxin expression and localization in human cell lines: detection of full-length and truncated species. Exp. Cell Res. 236:1997;181-192.
37. Jensen P.E. Antigen unfolding and disulfide reduction in antigen presenting cells. Semin. Immunol. 7:1995;347-353.
38. Arunachalam B., Phan U.T., Geuze H.J., Cresswell P. Enzymatic reduction of disulfide bonds in lysosomes: characterization of a gamma-interferon-inducible lysosomal thiol reductase (GILT). Proc. Natl. Acad. Sci. USA. 97:2000;745-750.
39. Noiva R., Lennarz W.J. Protein disulfide isomerase. A multifunctional protein resident in the lumen of the endoplasmic reticulum. J. Biol. Chem. 267:1992;3553-3556.
40. Shen W.C., Ryser H.J., LaManna L. Disulfide spacer between methotrexate and poly(D-lysine). A probe for exploring the reductive process in endocytosis. J. Biol. Chem. 260:1985;10905-10908.
41. Kang H.K., Mikszta J.A., Deng H., Sercarz E.E., Jensen P.E., Kim B.S. Processing and reactivity of T cell epitopes containing two cysteine residues from hen egg-white lysozyme (HEL74-90). J. Immunol. 164:2000;1775-1782.
42. Collins D.S., Unanue E.R., Harding C.V. Reduction of disulfide bonds within lysosomes is a key step in antigen processing. J. Immunol. 147:1991;4054-4059.
43. Steinberg T.H., Swanson J.A. Measurement of phagosome-lysosome fusion and phagosomal pH. Methods Enzymol. 236:1994;147-160.
44. Jensen P.E. Reduction of disulfide bonds during antigen processing: evidence from a thiol-dependent insulin determinant. J. Exp. Med. 174:1991;1121-1130.
45. Merkel B.J., Mandel R., Ryser H.J., McCoy K.L. Characterization of fibroblasts with a unique defect in processing antigens with disulfide bonds. J. Immunol. 154:1995;128-136.
46. Lloyd J.B. Disulphide reduction in lysosomes. The role of cysteine. Biochem. J. 237:1986;271-272.
47. Pisoni R.L., Acker T.L., Lisowski K.M., Lemons R.M., Thoene J.G. A cysteine-specific lysosomal transport system provides a major route for the delivery of thiol to human fibroblast lysosomes: possible role in supporting lysosomal proteolysis. J. Cell Biol. 110:1990;327-335.
48. Gainey D., Short S., McCoy K.L. Intracellular location of cysteine transport activity correlates with productive processing of antigen disulfide. J. Cell. Physiol. 168:1996;248-254.
49. Gahl W.A., Bashan N., Tietze F., Bernardini I., Schulman J.D. Cystine transport is defective in isolated leukocyte lysosomes from patients with cystinosis. Science. 217:1982;1263-1265.
50. Creighton T.E., Zapun A., Darby N.J. Mechanisms and catalysts of disulfide bond formation in proteins. Trends Biotechnol. 13:1995;18-23.
51. Phan U.T., Arunachalam B., Cresswell P. Gamma-interferon-inducible lysosomal thiol reductase (GILT). Maturation, activity, and mechanism of action. J. Biol. Chem. 275:2000;25907-25914.
52. Phan U.T., Maric M., Dick T.P., Cresswell P. Multiple species express thiol oxidoreductases related to GILT. Immunogenetics. 53:2001;342-346.
53. Luster A.D., Weinshank R.L., Feinman R., Ravetch J.V. Molecular and biochemical characterization of a novel gamma-interferon-inducible protein. J. Biol. Chem. 263:1988;12036-12043.
54. Glickman J.N., Morton P.A., Slot J.W., Kornfeld S., Geuze H.J. The biogenesis of the MHC class II compartment in human I-cell disease B lymphoblasts. J. Cell Biol. 132:1996;769-785.
55. Maric M., Arunachalam B., Phan U.T., Dong C., Garrett W.S., Cannon K.S., Alfonso C., Karlsson L., Flavell R.A., Cresswell P. Defective antigen processing in GILT-free mice. Science. 294:2001;1361-1365.
56. Mustacich D., Powis G. Thioredoxin reductase. Biochem. J. 346:2000;1-8.
57. Liu C. Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. Proc. Natl. Acad. Sci. USA. 93:1996;8618-8623.
58. Chari R.V. Enhancement of the selectivity and antitumor efficacy of a CC-1065 analogue through immunoconjugate formation. Cancer Res. 55:1995;4079-4084.
59. Hinman L.M., Hamann P.R., Wallace R., Menendez A.T., Durr F.E., Upeslacis J. Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. Cancer Res. 53:1993;3336-3342.
60. Ghetie V. Chemical construction of immunotoxins. Mol. Biotechnol. 18:2001;251-268.
61. Carlsson J., Drevin H., Axen R. Protein thiolation and reversible protein-protein conjugation. N-Succinimidyl 3-(2-pyridyldithio)propionate, a new heterobifunctional reagent. Biochem. J. 173:1978;723-737.
62. Thorpe P.E., Wallace P.M., Knowles P.P., Relf M.G., Brown A.N., Watson G.J., Knyba R.E., Wawrzynczak E.J., Blakey D.C. New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo. Cancer Res. 47:1987;5924-5931.
63. Willner D. (6-Maleimidocaproyl)hydrazone of doxorubicin - a new derivative for the preparation of immunoconjugates of doxorubicin. Bioconjug. Chem. 4:1993;521-527.
64. Wahl A.F., Donaldson K.L., Mixan B.J., Trail P.A., Siegall C.B. Selective tumor sensitization to taxanes with the mAb-drug conjugate cBR96-doxorubicin. Int. J. Cancer. 93:2001;590-600.
65. Woghiren C., Sharma B., Stein S. Protected thiol-polyethylene glycol: a new activated polymer for reversible protein modification. Bioconjug. Chem. 4:1993;314-318.
66. Cochran J.R., Cameron T.O., Stone J.D., Lubetsky J.B., Stern L.J. Receptor proximity, not intermolecular orientation, is critical for triggering T-cell activation. J. Biol. Chem. 276:2001;28068-28074.
67. Cochran J.R., Stern L.J. A diverse set of oligomeric class II MHC-peptide complexes for probing T-cell receptor interactions. Chem. Biol. 7:2000;683-696.
68. Kuan C.T., Wang Q.C., Pastan I. Pseudomonas exotoxin A mutants. Replacement of surface exposed residues in domain II with cysteine residues that can be modified with polyethylene glycol in a site-specific manner. J. Biol. Chem. 269:1994;7610-7616.
69. Park J.W., Kirpotin D.B., Hong K., Shalaby R., Shao Y., Nielsen U.B., Marks J.D., Papahadjopoulos D., Benz C.C. Tumor targeting using anti-her2 immunoliposomes. J. Controlled Release. 74:2001;95-113.
70. Gupta S., Eastman J., Silski C., Ferkol T., Davis P.B. Single chain Fv: a ligand in receptor-mediated gene delivery. Gene Ther. 8:2001;586-592.
71. Chapman A.P., Antoniw P., Spitali M., West S., Stephens S., King D.J. Therapeutic antibody fragments with prolonged in vivo half-lives. Nat. Biotechnol. 17:1999;780-783.
72. Vanwetswinkel S., Plaisance S., Zhi-Yong Z., Vanlinthout I., Brepoels K., Lasters I., Collen D., Jespers L. Pharmacokinetic and thrombolytic properties of cysteine-linked polyethylene glycol derivatives of staphylokinase. Blood. 95:2000;936-942.
73. Bailon P., Palleroni A., Schaffer C.A., Spence C.L., Fung W.J., Porter J.E., Ehrlich G.K., Pan W., Xu Z.X., Modi M.W., Farid A., Berthold W., Graves M. Rational design of a potent, long-lasting form of interferon: a 40-kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug. Chem. 12:2001;195-202.
74. Kozlowski A., Harris J.M. Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C. J. Controlled Release. 72:2001;217-224.
75. Niculescu-Duvaz I. Technology evaluation: gemtuzumab ozogamicin. Curr. Opin. Mol. Ther. 2:2000;691-696.
76. Wagner E., Zenke M., Cotten M., Beug H., Birnstiel M.L. Transferrin-polycation conjugates as carriers for DNA uptake into cells. Proc. Natl. Acad. Sci. USA. 87:1990;3410-3414.
77. Zenke M., Steinlein P., Wagner E., Cotten M., Beug H., Birnstiel M.L. Receptor-mediated endocytosis of transferrin-polycation conjugates: an efficient way to introduce DNA into hematopoietic cells. Proc. Natl. Acad. Sci. USA. 87:1990;3655-3659.
78. Erbacher P., Remy J.S., Behr J.P. Gene transfer with synthetic virus-like particles via the integrin-mediated endocytosis pathway. Gene Ther. 6:1999;138-145.
79. Wang L., Kristensen J., Ruffner D.E. Delivery of antisense oligonucleotides using HPMA polymer: synthesis of A thiol polymer and its conjugation to water-soluble molecules. Bioconjug. Chem. 9:1998;749-757.
80. Rajur S.B., Roth C.M., Morgan J.R., Yarmush M.L. Covalent protein-oligonucleotide conjugates for efficient delivery of antisense molecules. Bioconjug. Chem. 8:1997;935-940.
81. Kircheis R., Kichler A., Wallner G., Kursa M., Ogris M., Felzmann T., Buchberger M., Wagner E. Coupling of cell-binding ligands to polyethylenimine for targeted gene delivery. Gene Ther. 4:1997;409-418.
82. Kircheis R., Schuller S., Brunner S., Ogris M., Heider K.H., Zauner W., Wagner E. Polycation-based DNA complexes for tumor-targeted gene delivery in vivo. J. Gene Med. 1:1999;111-120.
83. Wagner E. Application of membrane-active peptides for non-viral gene delivery. Adv. Drug Deliv. Rev. 38:1999;279-289.
84. Wagner E., Plank C., Zatloukal K., Cotten M., Birnstiel M.L. Influenza virus hemagglutinin HA-2 N-terminal fusogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes: toward a synthetic virus-like gene-transfer vehicle. Proc. Natl. Acad. Sci. USA. 89:1992;7934-7938.
85. Bongartz J.P., Aubertin A.M., Milhaud P.G., Lebleu B. Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide. Nucleic Acids Res. 22:1994;4681-4688.
86. Haensler J., Szoka F.C. Jr. Polyamidoamine cascade polymers mediate efficient transfection of cells in culture. Bioconjug. Chem. 4:1993;372-379.
87. Ogris M., Carlisle R.C., Bettinger T., Seymour L.W. Melittin enables efficient vesicular escape and enhanced nuclear access of non-viral gene delivery vectors. J. Biol. Chem. 276:2001;47550-47555.
88. Legendre J.Y., Trzeciak A., Bohrmann B., Deuschle U., Kitas E., Supersaxo A. Dioleoylmelittin as a novel serum-insensitive reagent for efficient transfection of mammalian cells. Bioconjug. Chem. 8:1997;57-63.
89. Nir S., Nicol F., Szoka F.C. Jr. Surface aggregation and membrane penetration by peptides: relation to pore formation and fusion. Mol. Membr. Biol. 16:1999;95-101.
90. Plank C., Oberhauser B., Mechtler K., Koch C., Wagner E. The influence of endosome-disruptive peptides on gene transfer using synthetic virus-like gene transfer systems. J. Biol. Chem. 269:1994;12918-12924.
91. Lee H., Jeong J.H., Park T.G. PEG grafted polylysine with fusogenic peptide for gene delivery: high transfection efficiency with low cytotoxicity. J. Controlled Release. 79:2002;283-291.
92. Jacobs T., Darji A., Weiss S., Chakraborty T. Listeriolysin, the thiol-activated haemolysin of Listeria monocytogenes. Alouf J.E., Freer J.H. The Comprehensive Sourcebook of Bacterial Protein Toxins. 1999;511-521 Academic Press, London.
93. Iwamoto M., Ohno-Iwashita Y., Ando S. Role of the essential thiol group in the thiol-activated cytolysin from Clostridium perfringens. Eur. J. Biochem. 167:1987;425-430.
94. Cowell J.L., Grushoff-Kosyk P.S., Bernheimer A.W. Purification of cereolysin and the electrophoretic separation of the active (reduced) and inactive (oxidized) forms of the purified toxin. Infect. Immunol. 14:1976;144-154.
95. Clark A.G., Civetta A. Evolutionary biology. Protamine wars. Nature. 403:2000;261-263.
96. Perreault S.D., Barbee R.R., Slott V.L. Importance of glutathione in the acquisition and maintenance of sperm nuclear decondensing activity in maturing hamster oocytes. Dev. Biol. 125:1988;181-186.
97. McCarthy M.P., White W.I., Palmer-Hill F., Koenig S., Suzich J.A. Quantitative disassembly and reassembly of human papillomavirus type 11 virus-like particles in vitro. J. Virol. 72:1998;32-41.
98. Blessing T., Remy J.S., Behr J.P. Monomolecular collapse of plasmid DNA into stable virus-like particles. Proc. Natl. Acad. Sci. USA. 95:1998;1427-1431.
99. Trubetskoy V.S., Loomis A., Slattum P.M., Hagstrom J.E., Budker V.G., Wolff J.A. Caged DNA does not aggregate in high ionic strength solutions. Bioconjug. Chem. 10:1999;624-628.
100. Oupicky D., Carlisle R.C., Seymour L.W. Triggered intracellular activation of disulfide crosslinked polyelectrolyte gene delivery complexes with extended systemic circulation in vivo. Gene Ther. 8:2001;713-724.
101. Gosselin M.A., Guo W., Lee R.J. Efficient gene transfer using reversibly cross-linked low molecular weight polyethylenimine. Bioconjug. Chem. 12:2001;989-994.
102. McKenzie D.L., Kwok K.Y., Rice K.G. A potent new class of reductively activated peptide gene delivery agents. J. Biol. Chem. 275:2000;9970-9977.
103. Kakizawa Y., Harada A., Kataoka K. Glutathione-sensitive stabilization of block copolymer micelles composed of antisense DNA and thiolated poly(ethylene glycol)-block-poly(L-lysine): a potential carrier for systemic delivery of antisense DNA. Biomacromolecules. 2:2001;491-497.
104. Ishida T., Kirchmeier M.J., Moase E.H., Zalipsky S., Allen T.M. Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells. Biochim. Biophys. Acta. 1515:2001;144-158.
105. Papahadjopoulos D., Allen T.M., Gabizon A., et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. USA. 88:1991;11460-11464.
106. Drummond D.C., Zignani M., Leroux J. Current status of pH-sensitive liposomes in drug delivery. Prog. Lipid Res. 39:2000;409-460.
107. Kirpotin D., Hong K., Mullah N., Papahadjopoulos D., Zalipsky S. Liposomes with detachable polymer coating: destabilization and fusion of dioleoylphosphatidylethanolamine vesicles triggered by cleavage of surface-grafted poly(ethylene glycol). FEBS Lett. 388:1996;115-118.
108. Lindgren M., Hallbrink M., Prochiantz A., Langel U. Cell-penetrating peptides. Trends Pharmacol. Sci. 21:2000;99-103.
109. Nakanishi T., Hayashi A., Kunisawa J., Tsutsumi Y., Tanaka K., Yashiro-Ohtani Y., Nakanishi M., Fujiwara H., Hamaoka T., Mayumi T. Fusogenic liposomes efficiently deliver exogenous antigen through the cytoplasm into the MHC class I processing pathway. Eur. J. Immunol. 30:2000;1740-1747.
110. Spiller D.G., Giles R.V., Grzybowski J., Tidd D.M., Clark R.E. Improving the intracellular delivery and molecular efficacy of antisense oligonucleotides in chronic myeloid leukemia cells: a comparison of streptolysin-O permeabilization, electroporation, and lipophilic conjugation. Blood. 91:1998;4738-4746.
111. Derossi D., Chassaing G., Prochiantz A. Trojan peptides: the penetratin system for intracellular delivery. Trends Cell Biol. 8:1998;84-87.
112. Troy C.M., Derossi D., Prochiantz A., Greene L.A., Shelanski M.L. Downregulation of Cu/Zn superoxide dismutase leads to cell death via the nitric oxide-peroxynitrite pathway. J. Neurosci. 16:1996;253-261.
113. Allinquant B., Hantraye P., Mailleux P., Moya K., Bouillot C., Prochiantz A. Downregulation of amyloid precursor protein inhibits neurite outgrowth in vitro. J. Cell Biol. 128:1995;919-927.
114. Fahraeus R., Paramio J.M., Ball K.L., Lain S., Lane D.P. Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16CDKN2/INK4A. Curr. Biol. 6:1996;84-91.
115. Hallbrink M., Floren A., Elmguist A., Pooga M., Bartfai T., Langel U. Cargo delivery kinetics of cell-penetrating peptides. Biochim. Biophys. Acta. 1515:2001;101-109.
116. Jones D.P., Carlson J.L., Samiec P.S., Sternberg P. Jr., Mody V.C. Jr., Reed R.L., Brown L.A. Glutathione measurement in human plasma. Evaluation of sample collection, storage and derivatization conditions for analysis of dansyl derivatives by HPLC. Clin. Chim. Acta. 275:1998;175-184.
117. Jones D.P., Carlson J.L., Mody V.C., Cai J., Lynn M.J., Sternberg P. Redox state of glutathione in human plasma. Free Radic. Biol. Med. 28:2000;625-635.
118. Zalipsky S., Qazen M., Walker J.A. 2nd, Mullah N., Quinn Y.P., Huang S.K. New detachable poly(ethylene glycol) conjugates: cysteine-cleavable lipopolymers regenerating natural phospholipid, diacyl phosphatidylethanolamine. Bioconjug. Chem. 10:1999;703-707.
119. Senter P.D., Pearce W.E., Greenfield R.S. Development of a drug-release strategy based on the reductive fragmentation of benzyl carbamate disulfides. J. Org. Chem. 55:1990;2975-2978.
120. Zalipsky S., Kiwan R., Qazen M., et al. Proceedings of the International Symposium Control. Rel. Bioact. Mater., Controlled Release Society, San Diego, 2001. 2001;437-438.
121. Zalipsky S., Mullah N., Kiwan R. Proceedings of the International Symposium Control. Rel. Bioact. Mater., Controlled Release Society, San Diego, 2001. 2001;73-74.
122. Trimble S.P., Marquardt D., Anderson D.C. Use of designed peptide linkers and recombinant hemoglobin mutants for drug delivery: in vitro release of an angiotensin II analog and kinetic modeling of delivery. Bioconjug. Chem. 8:1997;416-423.
123. Letvin N.L., Goldmacher V.S., Ritz J., Yetz J.M., Schlossman S.F., Lambert J.M. In vivo administration of lymphocyte-specific monoclonal antibodies in non-human primates. In vivo stability of disulfide-linked immunotoxin conjugates. J. Clin. Invest. 77:1986;977-984.
124. Amlot P.L., Stone M.J., Cunningham D., Fay J., Newman J., Collins R., May R., McCarthy M., Richardson J., Ghetie V., et al. A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood. 82:1993;2624-2633.
125. Schnell R., Vitetta E., Schindler J., Borchmann P., Barth S., Ghetie V., Hell K., Drillich S., Diehl V., Engert A. Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin. Leukemia. 14:2000;129-135.
126. Arpicco S., Dosio F., Brusa P., Crosasso P., Cattel L. New coupling reagents for the preparation of disulfide cross-linked conjugates with increased stability. Bioconjug. Chem. 8:1997;327-337.
127. Dosio F., Arpicco S., Adobati E., Canevari S., Brusa P., De Santis R., Parente D., Pignanelli P., Negri D.R., Colnaghi M.I., Cattel L. Role of cross-linking agents in determining the biochemical and pharmacokinetic properties of Mgr6-clavin immunotoxins. Bioconjug. Chem. 9:1998;372-381.
128. Trail P.A. Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates. Cancer Res. 57:1997;100-105.
129. Hamann P.R., Hinman L.M., Beyer C.F., Lindh D., Upeslacis J., Flowers D.A., Bernstein I. An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjug. Chem. 13:2002;40-46.
130. Duncan R., Gac-Breton S., Keane R., Musila R., Sat Y.N., Satchi R., Searle F. Polymer-drug conjugates, PDEPT and PELT: basic principles for design and transfer from the laboratory to clinic. J. Controlled Release. 74:2001;135-146.
131. Umemoto N., Kato Y., Endo N., Takeda Y., Hara T. Preparation and in vitro cytotoxicity of a methotrexate-anti-MM46 monoclonal antibody conjugate via an oligopeptide spacer. Int. J. Cancer. 43:1989;677-684.
132. Umemoto N., Kato Y., Hara T. Cytotoxicities of two disulfide-bond-linked conjugates of methotrexate with monoclonal anti-MM46 antibody. Cancer Immunol. Immunother. 28:1989;9-16.
133. Hamann P.R., Hinman L.M., Hollander I., Beyer C.F., Lindh D., Holcomb R., Hallett W., Tsou H.R., Upeslacis J., Shochat D., Mountain A., Flowers D.A., Bernstein I. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug. Chem. 13:2002;47-58.
134. Trail P.A. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science. 261:1993;212-215. erratum appears in Science 263(5150) (1994) 1076.